Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era

This publication has 59 references indexed in Scilit:

• Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients
  International Journal of Hematology, 2025
• Post‐stem cell transplant maintenance in FLT3^mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
  eJHaem, 2024
• Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS
  International Journal of Hematology, 2023
• FLT3-targeted treatment for acute myeloid leukemia
  International Journal of Hematology, 2022
• FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
  International Journal of Hematology, 2022
• Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification
  American Journal of Hematology, 2022
• Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
  Clinical Pharmacokinetics, 2020
• Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis
  Cancer, 2016
• Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation
  International Journal of Hematology, 2016
• Defining the Intensity of Conditioning Regimens: Working Definitions
  Transplantation and Cellular Therapy, 2009